Cytori Therapeutics Proposes Public Offering of Common Stock

  Cytori Therapeutics Proposes Public Offering of Common Stock

Business Wire

SAN DIEGO -- December 13, 2012

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that it intends to
offer and sell shares of its common stock in an underwritten public offering.
The offering is subject to market conditions, and there can be no assurance as
to whether or when the offering may be completed, or as to the actual size or
terms of the offering. Cytori also expects to grant the underwriters a 30-day
option to purchase up to an additional 15% of the shares of common stock
offered in the public offering to cover over-allotments, if any. All of the
shares in the offering are to be sold by Cytori.

Lazard Capital Markets LLC is acting as the sole book-running manager of the
offering.

A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission (SEC) and declared effective by the SEC on May 9, 2011. A
preliminary prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the SEC’s web
site at www.sec.gov. When available, copies of the preliminary prospectus
supplement relating to these securities may also be obtained from the offices
of Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York,
NY, 10020 or via telephone at 800-542-0970.

This press release does not constitute an offer to sell or the solicitation of
an offer to buy any of these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.

About Cytori Therapeutics

Cytori Therapeutics, Inc. is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
repair soft tissue defects. Our scientific data suggest ADRCs improve blood
flow, moderate the immune response and keep tissue at risk of dying alive. As
a result, we believe these cells can be applied across multiple “ischemic”
conditions. These therapies are made available to the physician and patient at
the point-of-care by Cytori’s proprietary technologies and products, including
the Celution® system product family. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect Cytori’s future operating
results and financial position. Such statements, including, but not limited
to, those regarding statements about Cytori’s expectations regarding its
fundraising efforts, including the closing of the public offering and the
underwriter’s exercise of its over-allotment option, involve known and unknown
risks that relate to Cytori’s future events or future financial performance
and the actual results could differ materially from those discussed in this
communication. Risks and uncertainties that may cause Cytori’s actual results
to differ materially from those discussed in this communication can be found
in the “Risk Factors” section of Cytori’s Form 10-K, Forms 10-Q and its other
filings with the Securities and Exchange Commission. Readers are cautioned not
to place undue reliance on these forward-looking statements that speak only as
of the date hereof, and Cytori assumes no responsibility to update or revise
any forward-looking statements contained in this communication to reflect
events, trends or circumstances after the date of this communication.

Contact:

Cytori Therapeutics, Inc.
Investors
Tom Baker, +1-858-875-5258
tbaker@cytori.com
or
Media
Megan McCormick, +1-858-875-5279
mmccormick@cytori.com
 
Press spacebar to pause and continue. Press esc to stop.